Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

P8‐34: The relation between immune‐related adverse events and therapeutic effects of nivolumab or pembrolizumab monotherapy for patients with non‐small cell lung cancer

Respirology(2021)10.1111/resp.14150_546Source: DataRank Database

P8‐34: The relation between immune‐related adverse events and therapeutic effects of nivolumab or pembrolizumab monotherapy for patients with non‐small cell lung cancer is a research paper published in Respirology (2021). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: closedTopics (14)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Live enrichment

PubMed:23304386 OpenAlex:https://openalex.org/W4200529536

closed

journalhttps://doi.org/10.1111/resp.14150_546

Fields of Study

Cancer Immunotherapy and BiomarkersCancer, Stress, Anesthesia, and Immune ResponseColorectal Cancer Treatments and Studies

Keywords

MedicineNivolumabPembrolizumabLung cancerAdverse effectOncologyInternal medicineImmune systemImmunotherapyCancerImmunology

P8‐34: The relation between immune‐related adverse events and therapeutic effects of nivolumab or pembrolizumab monotherapy for patients with non‐small cell lung cancer

FAIR Checklist

Open Access

Topics